Essiac/Flor Essence (PDQ(R)): Health Professional Version
government report · 2002
SUMMARY
The National Cancer Institute's official, editorially-independent, continually-reviewed cancer-information summary on Essiac and Flor Essence. States that no controlled human-study data support efficacy against cancer, that the FDA has not approved either product for any medical condition, and documents the 1922 origin story, the 1977 transfer of the formula to a Canadian corporation, and the 1978-1982 Canadian federal review that withdrew research permission after the licensee failed to meet manufacturing-consistency and clinical-trial-design commitments. Directly fetched from https://www.ncbi.nlm.nih.gov/books/NBK66061/ 2026-08-17; identifier cross-confirmed via PubMed efetch.
NOTES
The single most load-bearing source in this case: an authoritative, current, government cancer-research-institute summary that both supplies the sourced institutional history (1922 origin, 1977 formula transfer, 1978-1982 regulatory review) and states plainly that no controlled data support Essiac’s use against cancer.